Skip to content
AnalystLens

Illumina 8-K Report, Financial Results (Feb 5, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed February 5, 2026
Period End
February 5, 2026
Security
ILMN
In the record · 2016–202610-K1110-Q338-K167

ILMN filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 167 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Sep ’19Sep ’19
  2. Deal closed8-K · Oct ’21Oct ’21
  3. Restructuring8-K · Jun ’23Jun ’23
  4. Leadership change8-K · Mar ’25Mar ’25

01—Abstract

Summary

Summary of the 8-K filed February 5, 2026. Cited figures are marked; the original filing is the authoritative source.

Illumina, Inc. reported fourth-quarter 2025 revenue of $1.16 billiona, up 5% from the prior-year quarter (up 4% on a constant currency basis), with ex-China revenue of $1.10 billion, up 8%.

GAAP diluted EPS was $2.16b and non-GAAP diluted EPS was $1.35. GAAP operating margin was 17.4% and non-GAAP operating margin was 23.7%. Q4 cash flow provided by operations was $321 million and free cash flow was $267 million.

The company ended the quarter with $1.63 billionc in cash, cash equivalents and short-term investments. For fiscal year 2025, revenue was $4.34 billion, flat compared with 2024 on both a reported and constant currency basis. Ex-China revenue was $4.10 billion, up 2%.

GAAP diluted EPS was $5.45d and non-GAAP diluted EPS was $4.84, with free cash flow of $931 million. Management attributed the return to growth to disciplined execution, citing momentum in clinical markets during the second half of the year. For fiscal 2026, Illumina guided to total company revenue of $4.5 billion to $4.6 billion, representing reported growth of 4% to 6%, including a 1.5% to 2.0% benefit from the recently closed SomaLogic acquisition.

Ex-China organic revenue growth is expected to be 2% to 4%. Non-GAAP operating margin is guided to 23.3% to 23.5%, including a negative 100 basis point impact from SomaLogic, and non-GAAP diluted EPS is guided to $5.05 to $5.20, including $0.18 of dilution from SomaLogic. This Form 8-K furnishes the earnings press release under Item 2.02 and is not deemed filed for purposes of Section 18 of the Exchange Act.

02—Key points

Key Highlights

  1. Q4 2025 revenue of $1.16 billion rose 5% year over year; ex-China revenue of $1.10 billion rose 8%.
  2. FY2025 revenue was flat at $4.34 billion, while ex-China revenue grew 2% to $4.10 billion.
  3. Q4 GAAP diluted EPS was $2.16 versus non-GAAP diluted EPS of $1.35; FY2025 GAAP diluted EPS was $5.45 versus non-GAAP $4.84.
  4. FY2026 guidance calls for revenue of $4.5 billion to $4.6 billion (4% to 6% reported growth, including a 1.5% to 2.0% SomaLogic benefit) and non-GAAP diluted EPS of $5.05 to $5.20.
  5. Free cash flow was $267 million in Q4 and $931 million for FY2025; the company held $1.63 billion in cash, cash equivalents and short-term investments at quarter end.
  6. The SomaLogic acquisition closed, and the company introduced the Billion Cell Atlas, its first BioInsight data product, with AstraZeneca, Merck and Eli Lilly as first pharmaceutical partners.
  7. China remains a factor: MOFCOM lifted the export ban on Illumina sequencers, but the company remains on China's Unreliable Entities List, requiring approvals for instrument purchases.

03—Questions

Frequently Asked Questions

  1. How did Illumina perform in the fourth quarter of 2025?

    Revenue was $1.16 billion, up 5% from Q4 2024 (up 4% on a constant currency basis). GAAP operating margin was 17.4% and non-GAAP operating margin was 23.7%. GAAP diluted EPS was $2.16 and non-GAAP diluted EPS was $1.35.

  2. What is Illumina's revenue outlook for fiscal 2026?

    The company expects total revenue of $4.5 billion to $4.6 billion, representing 4% to 6% reported growth, including a 1.5% to 2.0% benefit from the SomaLogic acquisition. Ex-China organic revenue growth is expected to be 2% to 4%.

  3. How will SomaLogic affect Illumina's fiscal 2026 profitability?

    The company expects non-GAAP operating margin of 23.3% to 23.5%, including a negative 100 basis point impact from SomaLogic. Non-GAAP diluted EPS is guided to $5.05 to $5.20, including $0.18 of dilution from the acquisition.

  4. What is the status of Illumina's business in China?

    The Chinese Ministry of Commerce lifted the export ban on Illumina sequencers. However, the company remains on the Unreliable Entities List in China, which requires approvals for instrument purchases. Ex-China revenue was $4.10 billion for fiscal 2025, up 2%.

  5. What was Illumina's cash position and free cash flow at year end?

    The company held $1.63 billion in cash, cash equivalents and short-term investments at the end of the quarter. Free cash flow was $267 million for Q4 2025 and $931 million for fiscal 2025.

04—Continue

← View all 8-K filings